Accelerate Diagnostics (NASDAQ:AXDX) Upgraded at StockNews.com

StockNews.com upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX) from a sell rating to a hold rating in a report issued on Monday morning.

Accelerate Diagnostics Stock Down 2.4 %

NASDAQ:AXDX opened at $1.61 on Monday. Accelerate Diagnostics has a 52 week low of $0.73 and a 52 week high of $5.23. The stock has a market capitalization of $40.31 million, a price-to-earnings ratio of -0.57 and a beta of 0.59. The firm has a 50 day moving average of $1.80 and a 200 day moving average of $1.51.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. boosted its stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the period. Griffin Asset Management Inc. owned approximately 6.26% of Accelerate Diagnostics worth $1,615,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.